Phase I study of 2'-deoxycoformycin in acute lymphoblastic leukemia.
暂无分享,去创建一个
S. Sallan | R. Ungerleider | J. Lipton | D. Johns | G. Rivera | S. Murphy | D. Poplack | J. Holcenberg | J. Blatt | D. Glaubiger | D. Johns | P. Venner | P. Venner | Jeffrey M. Lipton
[1] G. Reaman,et al. Diminished lymphoblast 5'-nucleotidase activity in acute lymphoblastic leukemia with T-cell characteristics. , 1979, The New England journal of medicine.
[2] J. Smyth,et al. Correlation of adenosine deaminase activity with cell surface markers in acute lymphoblastic leukemia. , 1978, Journal of Clinical Investigation.
[3] C. Cass,et al. Enhancement of 9-beta-d-arabinofuranosyladenine cytotoxicity to mouse leukemia L1210 in vitro by 2'-deoxycoformycin. , 1976, Cancer research.
[4] P. W. Woo,et al. A novel adenosine and ara‐a deaminase inhibitor, (R)‐3‐(2‐deoxy‐β‐D‐erythro‐pentofuranosyl)‐3,6,7,8‐tetrahydroimidazo[4,5 ‐d] [1,3]diazepin‐8‐ol , 1974 .
[5] E. Giblett,et al. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. , 1972, Lancet.